Yurika Nakagawa-Saito

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 12

Top Topics

Cell Cycle Arrest

Binding Protein

Top Venues

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Yurika Nakagawa-Saito, Yuta Mitobe, Keita Togashi, Shuhei Suzuki, Asuka Sugai, Senri Takenouchi, Kazuki Nakamura, Yukihiko Sonoda, Chifumi Kitanaka, Masashi Okada
The MDM2-p53 Axis Represents a Therapeutic Vulnerability Unique to Glioma Stem Cells. International journal of molecular sciences 25 (7) (2024)
Yurika Nakagawa-Saito, Yuta Mitobe, Keita Togashi, Shuhei Suzuki, Asuka Sugai, Senri Takenouchi, Kazuki Nakamura, Yukihiko Sonoda, Chifumi Kitanaka, Masashi Okada
The MDM2-p53 Axis Represents a Therapeutic Vulnerability Unique to Glioma Stem Cells. International journal of molecular sciences 25 (7) (2024)
Yurika Nakagawa-Saito, Yuta Mitobe, Keita Togashi, Shuhei Suzuki, Asuka Sugai, Senri Takenouchi, Kazuki Nakamura, Yukihiko Sonoda, Chifumi Kitanaka, Masashi Okada
The MDM2-p53 Axis Represents a Therapeutic Vulnerability Unique to Glioma Stem Cells. International journal of molecular sciences 25 (7) (2024)
Yurika Nakagawa-Saito, Yuta Mitobe, Keita Togashi, Shuhei Suzuki, Asuka Sugai, Senri Takenouchi, Kazuki Nakamura, Yukihiko Sonoda, Chifumi Kitanaka, Masashi Okada
The MDM2-p53 Axis Represents a Therapeutic Vulnerability Unique to Glioma Stem Cells. International journal of molecular sciences 25 (7) (2024)
Yuta Mitobe, Shuhei Suzuki, Kazuki Nakamura, Yurika Nakagawa-Saito, Senri Takenouchi, Keita Togashi, Asuka Sugai, Yukihiko Sonoda, Chifumi Kitanaka, Masashi Okada
CEP-1347 Boosts Chk2-Mediated p53 Activation by Ionizing Radiation to Inhibit the Growth of Malignant Brain Tumor Cells. International journal of molecular sciences 25 (17) (2024)
Keita Togashi, Shuhei Suzuki, Yuta Mitobe, Yurika Nakagawa-Saito, Asuka Sugai, Senri Takenouchi, Masahiko Sugimoto, Chifumi Kitanaka, Masashi Okada
CEP-1347 Dually Targets MDM4 and PKC to Activate p53 and Inhibit the Growth of Uveal Melanoma Cells. Cancers 16 (1) (2023)
Yurika Nakagawa-Saito, Yuta Mitobe, Shuhei Suzuki, Keita Togashi, Asuka Sugai, Chifumi Kitanaka, Masashi Okada
Domatinostat Targets the FOXM1-Survivin Axis to Reduce the Viability of Ovarian Cancer Cells Alone and in Combination with Chemotherapeutic Agents. International journal of molecular sciences 24 (13) (2023)
Yuta Mitobe, Shuhei Suzuki, Yurika Nakagawa-Saito, Keita Togashi, Asuka Sugai, Yukihiko Sonoda, Chifumi Kitanaka, Masashi Okada
The Novel MDM4 Inhibitor CEP-1347 Activates the p53 Pathway and Blocks Malignant Meningioma Growth In Vitro and In Vivo. Biomedicines 11 (7) (2023)
Yuta Mitobe, Shuhei Suzuki, Yurika Nakagawa-Saito, Keita Togashi, Asuka Sugai, Yukihiko Sonoda, Chifumi Kitanaka, Masashi Okada
Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells. Cancers 15 (17) (2023)
Keita Togashi, Shuhei Suzuki, Yuta Mitobe, Yurika Nakagawa-Saito, Asuka Sugai, Senri Takenouchi, Masahiko Sugimoto, Chifumi Kitanaka, Masashi Okada
CEP-1347 Dually Targets MDM4 and PKC to Activate p53 and Inhibit the Growth of Uveal Melanoma Cells. Cancers 16 (1) (2023)
Masashi Okada, Yurika Nakagawa-Saito, Yuta Mitobe, Asuka Sugai, Keita Togashi, Shuhei Suzuki, Chifumi Kitanaka
Inhibition of the Phospholipase Cε-c-Jun N-Terminal Kinase Axis Suppresses Glioma Stem Cell Properties. International journal of molecular sciences 23 (15) (2022)
Yurika Nakagawa-Saito, Shinichi Saitoh, Yuta Mitobe, Asuka Sugai, Keita Togashi, Shuhei Suzuki, Chifumi Kitanaka, Masashi Okada
HDAC Class I Inhibitor Domatinostat Preferentially Targets Glioma Stem Cells over Their Differentiated Progeny. International journal of molecular sciences 23 (15) (2022)